Cellular immune response from Chagasic patients to CRA or FRA recombinant antigens of Trypanosoma cruzi.
We propose to analyze the relation between the cellular immune response of Chagas' disease patients after in vitro stimulation of peripheral blood mononuclear cells (PBMC) with recombinant antigens cytoplasmatic repetitive antigen (CRA) or flagellar repetitive antigen (FRA) of T. cruzi and the chronic clinical forms of disease. Cells were stimulated using phytohemagglutinin, CRA, FRA, or a soluble antigen of Epimastigota (Ag-Epi) for 24 hr, 72 hr, or 6 days. The proliferation of cells was evaluated after 6 days of culture by quantification of incorporated 3H-thymidine. Cytokines were measured in the supernatants obtained after 24 hr (tumor necrosis factor [TNF]-alpha and interleukin [IL]-4), 72 hr (IL-10), and 6 days (interferon [IFN]-gamma) using enzyme-linked immunosorbent assay (ELISA). Cells of the Chagas patients stimulated with the recombinant antigens exhibited higher proliferation responses compared with that of non-Chagas (NC) individuals. However, when proliferation was compared between patients with the cardiac form (CF) or indeterminate form (IF), it was not possible to establish a difference in the response. So far as the cytokines secreted in the culture supernatants after stimulation in vitro with T. cruzi antigens were concerned, the results showed that CRA, as well as Epi-Ag, were able to stimulate the production of TNF-alpha and IFN-gamma in Chagas patients as compared with NC individuals. However, the cytokine levels after stimulation with the T. cruzi antigens were not different between the patients with CF and IF. CRA was capable of inducing a T helper type 1 (Th1) immune response, with elevated production of TNF-alpha and IFN-gamma in Chagas patients that are carriers of CF and IF clinical forms.
Lorena
Virginia M B
VM
Departamento de Imunologia, Centro de Pesquisas Aggeu Magalhães/Fiocruz, Recife-PE, Brazil.
Verçosa
Alinne F A
AF
Machado
Raquel C A
RC
Moitinho-Silva
Lucas
L
Cavalcanti
Maria G A
MG
Silva
Edimilson D
ED
Ferreira
Antonio G P
AG
Correa-Oliveira
Rodrigo
R
Pereira
Valéria R A
VR
Gomes
Yara M
YM
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology*; D002353:Carrier State / Q000469:parasitology; D002478:Cells, Cultured; D014355:Chagas Disease / Q000276:immunology* / Q000469:parasitology*; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology*; D007371:Interferon-gamma / Q000276:immunology; D016753:Interleukin-10 / Q000276:immunology; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000469:parasitology; D008297:Male; D008875:Middle Aged; D008934:Mitogens / Q000494:pharmacology; D011994:Recombinant Proteins / Q000276:immunology*; D013347:Subcellular Fractions / Q000187:drug effects / Q000469:parasitology; D014349:Trypanosoma cruzi / Q000187:drug effects / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D000953:Antigens, Protozoan; D008934:Mitogens; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D007371:Interferon-gamma